Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/164895
Title: | Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial |
Author: | Mora, Jesús S. Genge, Angela Chio, Adriano Estol, Conrado J. Chaverri, Delia Hernández, María Marín, Saúl Mascias, Javier Rodríguez, Gabriel E. Povedano, Mònica Paipa, Andres Julian Domínguez, Raúl Gamez, Josep Salvado, Maria Lunetta, Christian Ballario, Carlos Riva, Nilo Mandrioli, Jessica Moussy, Alain Kinet, Jean-Pierre Auclair, Christian Dubreuil, Patrice Arnold, Vincent Mansfield, Colin D. Hermine, Olivier The Ab10015 Study Group |
Keywords: | Assaigs clínics Terapèutica Proteïnes quinases Clinical trials Therapeutics Protein kinases |
Issue Date: | 7-Jul-2019 |
Publisher: | Informa UK Limited |
Abstract: | Objective: To assess masitinib in the treatment of ALS. Methods: Double-blind study, randomly assigning 394 patients (1:1:1) to receive riluzole (100 mg/d) plus placebo or masitinib at 4.5 or 3.0 mg/kg/d. Following a blinded transition from phase 2 to phase 2/3, a prospectively defined two-tiered design was implemented based on ALSFRS-R progression rate from disease-onset to baseline (ΔFS). This approach selects a more homogeneous primary efficacy population (“Normal Progressors”, ΔFS < 1.1 points/month) while concurrently permitting secondary assessment of the broader population. Primary endpoint was decline in ALSFRS-R at week-48 (ΔALSFRS-R), with the high-dose “Normal Progressor” cohort being the prospectively declared primary efficacy population. Missing data were imputed via last observation carried forward (LOCF) methodology with sensitivity analyses performed to test robustness. Results: For the primary efficacy population, masitinib (n = 99) showed significant benefit over placebo (n = 102) with a ΔALSFRS-R between-group difference (ΔLSM) of 3.4 (95% CI 0.65–6.13; p = 0.016), corresponding to a 27% slowing in rate of functional decline (LOCF methodology). Sensitivity analyses were all convergent, including the conservative multiple imputation technique of FCS-REGPMM with a ΔLSM of 3.4 (95% CI 0.53–6.33; p = 0.020). Secondary endpoints (ALSAQ-40, FVC, and time-to-event analysis) were also significant. Conversely, no significant treatment-effect according to ΔALSFRS-R was seen for the broader “Normal and Fast Progressor” masitinib 4.5 mg/kg/d cohort, or either of the low-dose (masitinib 3.0 mg/kg/d) cohorts. Rates of treatment-emergent adverse events (AEs) (regardless of causality or post-onset ΔFS) were 88% with masitinib 4.5 mg/kg/d, 85% with 3.0 mg/kg/d, and 79% with placebo. Likewise, rates of serious AE were 31, 23, and 18%, respectively. No distinct event contributed to the higher rate observed for masitinib and no deaths were related to masitinib. Conclusions: Results show that masitinib at 4.5 mg/kg/d can benefit patients with ALS. A confirmatory phase 3 study will be initiated to substantiate these data. |
Note: | Reproducció del document publicat a: https://doi.org/10.1080/21678421.2019.1632346 |
It is part of: | Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, vol. 21, issue. 1, p. 5-14 |
URI: | http://hdl.handle.net/2445/164895 |
Related resource: | https://doi.org/10.1080/21678421.2019.1632346 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Masitinib_Mora_2020.pdf | 753.12 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License